Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Accounting Officer | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,033 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 101 · Balance 18,033 F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:10 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 101 | $2.01 | $203.01 |
DisclosureSEC source: 0000905148-26-003840 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,033 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:31 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 14,227 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002556 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,134 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:11 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $1.92 | $190.08 |
DisclosureSEC source: 0000905148-26-002502 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,907 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:22 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 31,900 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001121 · form4.xml · derivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,900 Underlying: Common Stock · 31,900 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:14 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 116 | $1.63 | $189.08 |
DisclosureSEC source: 0000905148-26-000939 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,006 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2025 Filed Nov 18, 2025 21:33 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $2.24 | $221.76 |
DisclosureSEC source: 0000905148-25-004131 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,122 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 21:19 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $1.39 | $137.61 |
DisclosureSEC source: 0000905148-25-003043 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,221 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:21 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $1.14 | $112.86 |
DisclosureSEC source: 0000905148-25-001824 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,320 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 22:36 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 31,900 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000905148-25-000842 · form4.xml · derivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,900 Underlying: Common Stock · 31,900 shares Expires 2035-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:00 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 116 | $5.42 | $628.72 |
DisclosureSEC source: 0000905148-25-000730 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,419 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:32 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $7.92 | $784.08 |
DisclosureSEC source: 0000905148-24-003228 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,535 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:53 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $7.02 | $694.98 |
DisclosureSEC source: 0000905148-24-002283 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,634 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:05 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 99 | $8.36 | $827.64 |
DisclosureSEC source: 0000905148-24-001495 · form4.xml · nonDerivative · entry 1 Peterson Katharine · CIK 0002022214 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,733 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.